Department of Geriatrics, Evangelisches Krankenhaus Göttingen-Weende, Göttingen, Germany.
Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
Front Immunol. 2023 Aug 16;14:1180785. doi: 10.3389/fimmu.2023.1180785. eCollection 2023.
Urinary tract infections are a major cause of the consumption of antibiotics in humans.
We studied the effect of a vaccine (StroVac®, containing inactivated bacteria and used to prevent recurrent urinary tract infections) licensed in Germany on the release of pro-inflammatory cytokines and the phagocytosis of () in primary murine macrophages and the macrophage cell line J774A.1.
StroVac® increased the release of the cytokines TNF-α, IL-6, IL-12/23 p40, and IL-1β and stimulated the phagocytosis of in a dose-dependent manner. This effect was independent of LPS as shown by the use of macrophages isolated from LPS-resistant C3H/HeJ mice. At concentrations up to 30 mg/l it was not toxic to bacteria or eukaryotic cells.
StroVac® does not only act via the adaptive but also by stimulating the innate immune system. This stimulation may help to build trained innate immunity against bacterial pathogens involved in recurrent urinary tract infections.
尿路感染是人类使用抗生素的主要原因之一。
我们研究了一种在德国获得许可的疫苗（StroVac®，包含已灭活的细菌，用于预防复发性尿路感染）对原代鼠巨噬细胞和巨噬细胞系 J774A.1 中促炎细胞因子释放和吞噬作用的影响。
StroVac®以剂量依赖性方式增加细胞因子 TNF-α、IL-6、IL-12/23 p40 和 IL-1β 的释放，并刺激的吞噬作用。这种作用独立于 LPS，如使用来自 LPS 抗性 C3H/HeJ 小鼠的巨噬细胞所证明的那样。在高达 30mg/L 的浓度下，它对细菌或真核细胞没有毒性。
StroVac®不仅通过适应性免疫系统发挥作用，还通过刺激先天免疫系统发挥作用。这种刺激可能有助于建立针对复发性尿路感染相关细菌病原体的训练有素的先天免疫。
Zotero 插件
